title: Ipilimumab: a potential immunologic agent in the treatment of metastatic castration-resistant prostate cancer.
abstract: Immunotherapy has garnered an important place in the therapeutic landscape of treatment in prostate cancer since approval of sipuleucel-T. Ipilimumab is a checkpoint inhibitor that is currently approved for the treatment of advanced melanoma. In the June issue of Lancet Oncology, Kwon and colleagues report the phase III trial using ipilimumab in a post-docetaxel metastatic castration-resistant prostate cancer population. While the primary endpoint of overall survival was not met, several lessons are learned from the analysis of this trial. Perhaps better refinement of a more favorable group of patients who may potentially benefit from an immunologic treatment should be advocated.
authors.affiliation: Department of Internal Medicine; George Washington University Medical Center; Washington, DC USA.
authors.forename: Adam
authors.initials: A
authors.lastname: Kittai
authors.affiliation: Department of International Medicine Programs; George Washington University; Washington, DC USA.
authors.forename: Mariam
authors.initials: M
authors.lastname: Meshikhes
authors.affiliation: Division of Hematology/Oncology; Department of Medicine; George Washington University Medical Center; Washington, DC USA.
authors.forename: Jeanny B
authors.initials: JB
authors.lastname: Aragon-Ching
mesh_terms: D019496:Cancer Vaccines / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy; D018799:Intercellular Adhesion Molecule-1 / Q000627:therapeutic use*; D008297:Male; D011471:Prostatic Neoplasms / Q000628:therapy*; D014020:Tissue Extracts / Q000627:therapeutic use*
chemical_list: D019496:Cancer Vaccines; D014020:Tissue Extracts; D018799:Intercellular Adhesion Molecule-1
keywords: ipilimumab; prostate cancer